Data quality and feedback from the assessment on 2000 and 2001 TDI data 1 EMCDDA, TDI meeting, 23/24 June 2003 Luis Royuela.

Slides:



Advertisements
Similar presentations
Estimating incidence of heroin use from treatment data presentation for TDI expert meeting Lucas Wiessing (EMCDDA), Lucilla Ravà and Carla Rossi (Univ.
Advertisements

TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.
European facility survey questionnaire (EFSQ) Treatment CUP.
Quality feedback: Validation of TDI Standard Table submitted in 2005 (2004 data) Sandrine Sleiman, Xavier Poos September 2006.
Working Group on coverage of Treatment Demand Data Lisbon, 5 February 2007.
Healthy life expectancy in the EU 15 Carol Jagger EHEMU team Europe Blanche XXVI Living Longer but Healthier lives Budapest November 2005.
Systems Analysis, Prototyping and Iteration Systems Analysis.
June 19, Proposal: An overall Plan Design to obtain answer to the research questions or problems Outline the various tasks you plan to undertake.
17 September SME Statistics OECD Workshop SME data and methodologies in the EU - item 5 Paul Feuvrier / Eurostat.
Enhancing Data Quality of Distributive Trade Statistics Workshop for African countries on the Implementation of International Recommendations for Distributive.
Bill Edgar (Dundee University) Matt Harrison (RIS) Volker Busch-Geertsema (GISS) European Commission MPHASIS Mutual Progress on Homelessness through Advancing.
Quality assurance -Population and Housing Census Alma Kondi, INSTAT, Albania.
Strenghtening collaboration with Serbia - IPA4 Project expected outcomes Frédéric Denecker, Programme Management Officer Reitox and International Cooperation.
Presenting information
UIS Data gathering mechanisms Said Voffal Kampala, 6 May 2008.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
The European Trade Association of the digital and interactive marketing industry representing the National trade associations and Corporate members European.
Sub-session 1B: General Overview of CRVS systems.
Estimation of the Prevalence of Problem Drug Use in Lithuania Dr Gordon Hay Centre for Drug Misuse Research University of Glasgow, United Kingdom.
Quality Assurance at the European Monitoring Centre for Drugs and Drug Addiction Sandrine Sleiman European Conference on Quality in Official Statistics,
National Research and Development Centre for Welfare and Health Knowledge for welfare and health1 Finnish Drug Treatment Information System Kristiina Kuussaari,
Jennifer Hillebrand, „Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European Countries”, 18 October 2007 Improving drug treatment.
Treatment system-based data collection: an integrated approach to monitoring Expert meeting: Implementation of the treatment strategy EMCDDA Lisbon,
Use of survey (LFS) to evaluate the quality of census final data Expert Group Meeting on Censuses Using Registers Geneva, May 2012 Jari Nieminen.
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
United Nations Regional Workshop on the 2010 World Programme on Population and Housing Censuses: Census Evaluation and Post Enumeration Surveys Bangkok,
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
26 June 2008 DG REGIO Evaluation Network Meeting Ex-post Evaluation of Cohesion Policy Programmes co-financed by the European Fund for Regional.
Erik Iversen, Norway Workshop at the annual TDI expert meeting EMCDDA, Lisbon 25 September 2006 Data Coverage Assessment The Bergen Clinics Foundation,
HCV in injecting drug users: developing indicators of prevalence and responses VHPB WHO Consultation Meeting Geneva, 13 May 2002 Lucas Wiessing European.
Global Toolkit on Treatment Demand Data State of Progress Michael Donmall (Co-ordinator Joint Project) N ational D rug E vidence C entre.
Linda Montanari, Buenos Aires, October 2003 CICAD/OAS, Demand Reduction Experts Group Meeting The Information System on Treatment Demand in EU EMCDDA.
Module 1 General introduction to substitution treatment.
Mats Wallin Swedish Univ. of Agricultural Sciences Dept. of Environmental Assessment Catarina Johansson Swedish Environmental Protection Agency Development.
Chapter 3: Software Project Management Metrics
Copyright 2010, The World Bank Group. All Rights Reserved. Managing Data Processing Section B.
Data sources of the EuroGroups Register Presentation by Eurostat
Treatment Prevalence Project Background information Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013.
2014 HIV/AIDS Surveillance in the European Union and European Economic Area (EU/EEA) European Centre for Disease Prevention and Control, Stockholm WHO.
Health care trajectories and medication consumption of substance users in treatment : linking TDI and IMA databases (Belgium) De Ridder Karin, Antoine.
Estimation of emigration flows by using immigration figures in receiving countries Michel POULAIN GéDAP UCL Belgium.
HIV surveillance in Northern Ireland 2013 An analysis of data for the calendar year 2012.
2010 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
INTERNATIONAL MIGRATION DATA as input for population projections Anne HERM and Michel POULAIN Estonian Interuniversity Population Research Centre, Estonia.
EMCDDA Treatment data collection strategy - progress report May 09 Dagmar Hedrich, on behalf of the TWG Presentation at the meeting of the Scientific Committee,
September 12-14, 2006OECD-Eurostat Expert Meeting1 OECD-Eurostat Expert Meeting on Trade in Services Statistics Foreign Affiliates Statistics in Eurostat.
Report on the work of the TF on SME Data item 6 of the agenda Structural Business Statistics Working Group 14 April 2015, Luxembourg Tatiana Mrlianová.
Census Office Fernando Casimiro Geneva, July 2010 Portugal – Census results tailored to user needs «
USAGE OF DRUGS IN EUROPE LSD CANNABIS. ALL ADULTS (15-64) USAGE OF LSD IN EUROPE All adults (15-64) Usage of LSD in Europe datesample sizemalefemaletotal.
Workshop on MDG, Bangkok, Jan.2009 MDG 3.2: Share of women in wage employment in the non-agricultural sector National and global data.
Janusz Sierosławski, Jacek Moskalewicz
Data Coverage in the Czech Republic
Freya Vander Laenen STRUCTURED SESSION Costs of drug treatment
4.1. Data Quality 1.
Table 1. Number and rate of reported confirmed syphilis cases per 100 000 population by country and year, EU/EEA, 2010–2014 Country
Selection of cities Anastasios Maroudas Eurogramme
Linda Montanari Programme P1: Monitoring the Situation
HIV/AIDS Surveillance in Europe 2011
Working Group on Population and Housing Censuses
Gonorrhoea cases of gonorrhoea were reported by 27 EU/EEA Member States for The overall notification rate was 18.8 cases per 100 000 population.
In-Depth Assessment (IDA) of MS submissions for MSFD article 8, 9 & 10 compiled and presented by Nikolaos Zampoukas based on material provided by V.
Treatment Prevalence Project Draft Guidelines
Development of a protocol for identification of reference conditions, and boundaries between high, good and moderate status in lakes and watercourses (REFCOND)
Update on the MIS risk assessment notes
CEF e-Invoicing Readiness Checker
"Environmental Expenditure Statistics"
Surveillance of Tuberculosis
Marleen De Smedt Geoffrey Thomas Cynthia Tavares
Skopje, 21 November 2017, General Population Survey results– launch
PRODCOM Working Group JMO M November 2012
Presentation transcript:

Data quality and feedback from the assessment on 2000 and 2001 TDI data 1 EMCDDA, TDI meeting, 23/24 June 2003 Luis Royuela.

-Introduction -Years covered and reporting period -Coverage: Geographical and Agencies -Availability of TDI items and comparability with TDI standards. -Completeness of each tables. -Double-counting. -Internal consistency. -Other problems. -Modification of TDI tables. -Conclusion. -Recommendations Data quality and feedback from the assessment on 2000 and 2001TDI data 2

Introduction Objective of indicator To provide comparable, reliable and anonymous information on the number and characteristics of people treated for their drug use in the Member States. Epidemiological -Description of the profile of drug users within Europe. -Identification of patterns of use. -Changes in patterns of use. 3 Management -Which is the population we are interested in and why? -What are the obstacles in getting this information? Purpose of information: REITOX sub-task 3.1 REITOX sub-task 3.2 REITOX sub-task 6.1 Procedures to avoid double counting in drug treatment reporting systems Feasibility study on the implementation of the proposals given in the final reports of REITOX sub-tasks on improving the quality and comparability of treatment reporting systems TDI protocol December ACTIVITIES CARRIED OUT SO FAR.

General Objective: Analysis of TDI data available in the EU member states in order to define a basic “profiles” of clients in treatment. Introduction Implementation of data quality in the EU member states and analysis of aggregated data in order to define a “basic profile of clients in treatment”. 4 Specific Objectives: I.To make data ready for analysis, through a detailed data check II.Assess quality of TDI data III. To identify methodological problems, in the data collected, which could affect the quality of the analysis outputs. IV.To transform data for analysis. V.To define analysis outputs. VI.Final report

Years covered and reporting period 5 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Outpatient data available in TDI Tables Not available Available 6 Geographical coverage Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Agency and clients coverage 7 (1) N of units covered: number of outpatient treatment centres reporting to the monitoring system (2) N of units in the country: Number of outpatient treatment centres that exist in the country. (3) % of centres covered: estimated proportion of reporting outpatient treatment centres, with regard to the overall number of the outpatient treatment centre in the country covered by the monitoring system. (4) % of cases covered: proportion of cases/episodes reported to the monitoring system with regard to all cases treated nationally.

OUTPATIENTS 8 Agency coverage Not Known 10% - 30%31% - 70%> 70% Estimated proportion of reporting treatment centres (with regard to the overall number of the respective treatment centre type in the country) covered by the monitoring system. Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Inpatient data available in TDI Tables Not available Available Geographical coverage 9 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Low threshold agencies data available in TDI Tables Not available Available 10 Geographical coverage Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

G.P. data available in TDI Tables Not available Available 11 Geographical coverage Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Treatment units in prison data available in TDI Tables Not available Available 12 Geographical coverage Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Comparability with TDI items BelgiumIntegrating the system in one national system. Not all items covered. Denmark Not all items covered. Minor conversions needed to fit categories of the TDI items. Germany Not all items covered. Some Items with multiple answers. Greece Not all items covered. Minor conversions needed to fit categories of the TDI items. SpainNot all items covered. Minor conversions needed to fit categories of the TDI items. FranceMoving to system based on TDI. IrelandNot all items covered. ItalyIntegrating the system in one national system. Luxemburg No specific problems NetherlandsNot all items covered. AustriaImplementing data collection according to TDI Protocol PortugalPortugal is in a pilot phase FinlandNot all items covered. SwedenNo specific problems United Kingdom Not all items covered. Categories route of administration do not match TDI categories. 13

Completeness of TDI tables 14

1. Missing values: Primary drug. Definition: The main drug is defined as the drug that causes the client the most problems. - Based on problems as defined by clients - Based on the ICD 10 diagnoses. Completeness of TDI tables 15 Records which primary drug is not known. Should be excluded?

Double-counting TDI collects information on persons who start treatment for their drug use at a treatment centre during a given period of time. (one calendar year). Each person should be counted only once in the period. 16

Double-counting. 17 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Internal inconsistency Impossibility to know the real number of: - Males - Females - Drugs - And other variables Increases the delay of the data analysis due to: - Have to request for correction. - Have to wait for the answer. 18

Internal inconsistency 19 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Internal inconsistency 20 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Internal inconsistency 21 Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

22 Internal inconsistency Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

23  Ten countries were included in the analysis. Denmark Germany Greece Spain Ireland Italy Luxemburg Netherlands Sweden Finland Only one did not present any problem. Two presented minor problems. Seven presented serious problems. Internal inconsistency Source: REITOX National Focal Points. TDI detailed tables EMCDDA..

Other problems 24  It is a HARD WORK filling in all TDI tables. oTakes many hours. oProbability of error is high. oThe cross check of the tables, to ensure they have the same information as the source, is a very complex process.  Facilitate the work of people responsible at NFPs. oStudy the modification of the tables. oStudy methods to automate the process: 1.For filling in tables. (SPSS-SAS) 2.For data checking. (Validation tables)

Modification of the tables. 25  Fundamental aim to go ahead with a modification: oIncrease and ensure the quality of data.  How data should be collected would depend on what we are going to do with the data. oDescribe general characteristics of clients in drug treatment of EU member states? oComparative analysis?

Modification of the tables 26  First option: 1.ADD a new column and row for missing values 2.Modify the formulas to allow ceros.

Modification of the tables. 27  Second option: 1.ADD a new column and row for missing values 2.Drop table 4. Previously treated. 3.Double table 14. 1st drug x ever treated by gender. 4.Drop table 7. Age x gender. (Same data in 14.1,2,3) 5.Drop 19.1,2,3 Other drug x age. 6.Double 9. Living status (with whom) 10. Living status (where) 11. Nationality by first treatment 7.Drop 20. Ever injected 8.Double 20.1 Ever injected (drugs) by gender. 9.ADD a table for missing and a validation table.

Modification of the tables. 28  Third option: Same structure for all the tables. 1. All cross-tabulations: All Treatments MENTDI Items Drugs Opiates WOMENTDI Items Drugs Opiates First Treatments MENTDI Items Drugs Opiates WOMENTDI Items Drugs Opiates ADD a table for missing and a validation table.

Modification of the tables. 29  Fourth option: Create a databank on National Treatment Demand. 1.Report individual records. (On a voluntary basis?) 2.Report TDI tables.

Data aggregation at EU level: Databank on National Treatment Demand 1.Better control of the data and increase of quality. 2.No Influence on the level of data protection -Confidentiality (identification variables should not be reported). 3.Extraordinary increase of the power and richness of the data analysis. 30

Conclusions 31 1.Not ALL European Member States report TDI data annually. 2.Quite good geographical coverage of outpatient data in EU, but there is low coverage of agencies and clients in some Member States. 3.Internal inconsistency were found in nine of the countries with data available. 4.There is a high probability of error when TDI tables are filled in. 5.Now is the best moment to face the modification of the reporting system before the new members join it. 6.Still have a long way to go until TDI is used to establish a standard baseline for comparisons.

Recommendations 32 1.Data quality and reliability should be improved. 2.Concentrate efforts on outpatients and inpatients and improve the coverage of agencies and clients in a 1 st phase. 3.Improve the data collection of the other type of units in the next phase. 4.Simplify spreadsheet. The best way to avoid internal inconsistency and facilitate the filling in of the tables is to uniform the structure of the tables. 5.Make more use of the data, analysis and dissemination. 6.TDI should be used to establish a standard baseline for comparisons. 7.Create a databank on National Treatment Demand.